SLC5A2 and chronic kidney disease: Currently, the causes of the increased prevalence of NA-CKD and NA-DKD could be related to the widespread use of renin-angiotensin system blockers and their combinations with the new classes of hypoglycaemic agents, including sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP1-RAs).